AR117091A1 - Anticuerpos monoclonales antagonistas contra cd40 y sus usos - Google Patents
Anticuerpos monoclonales antagonistas contra cd40 y sus usosInfo
- Publication number
- AR117091A1 AR117091A1 ARP190103362A ARP190103362A AR117091A1 AR 117091 A1 AR117091 A1 AR 117091A1 AR P190103362 A ARP190103362 A AR P190103362A AR P190103362 A ARP190103362 A AR P190103362A AR 117091 A1 AR117091 A1 AR 117091A1
- Authority
- AR
- Argentina
- Prior art keywords
- antibodies
- monoclonal antibodies
- activity
- antagonists against
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Abstract
Anticuerpos que se fijan a CD40, que incluyen un anticuerpo humanizado. Los anticuerpos se fijan a CD40 y no exhiben actividad agonista de CD40. Los anticuerpos pueden comprender un dominio Fc de lgG1 modificado y exhibir activación mínima de células dendríticas inmaduras. También, composiciones que comprenden anticuerpos, métodos de uso para el tratamiento de enfermedades que incluyen la actividad de CD40, y el uso en la preparación de un medicamento para el tratamiento de una enfermedad que incluye la actividad de CD40.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862769514P | 2018-11-19 | 2018-11-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR117091A1 true AR117091A1 (es) | 2021-07-07 |
Family
ID=68848451
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP190103362A AR117091A1 (es) | 2018-11-19 | 2019-11-15 | Anticuerpos monoclonales antagonistas contra cd40 y sus usos |
Country Status (19)
Country | Link |
---|---|
US (5) | US11261258B2 (es) |
EP (1) | EP3883652A1 (es) |
JP (2) | JP7271666B2 (es) |
KR (1) | KR102627246B1 (es) |
CN (2) | CN113164781B (es) |
AR (1) | AR117091A1 (es) |
AU (1) | AU2019385331A1 (es) |
BR (1) | BR112021009140A2 (es) |
CA (1) | CA3120358C (es) |
CL (1) | CL2021001230A1 (es) |
CO (1) | CO2021007691A2 (es) |
EA (1) | EA202191359A1 (es) |
IL (1) | IL283104A (es) |
MX (1) | MX2021005565A (es) |
PE (1) | PE20211293A1 (es) |
SG (1) | SG11202104776VA (es) |
TW (1) | TWI800694B (es) |
WO (1) | WO2020106620A1 (es) |
ZA (1) | ZA202103353B (es) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2923143T3 (es) | 2017-05-25 | 2022-09-23 | Bristol Myers Squibb Co | Anticuerpos monoclonales antagonistas contra CD40 y sus usos |
AR117091A1 (es) | 2018-11-19 | 2021-07-07 | Bristol Myers Squibb Co | Anticuerpos monoclonales antagonistas contra cd40 y sus usos |
BR112023002803A2 (pt) | 2020-08-25 | 2023-03-14 | Bristol Myers Squibb Co | Método de tratamento de uma doença autoimune com anticorpos monoclonais cd40 antagonísticos |
CN116963774A (zh) | 2021-01-28 | 2023-10-27 | 瑞泽恩制药公司 | 用于治疗细胞因子释放综合征的组合物和方法 |
CN115768477A (zh) * | 2021-06-29 | 2023-03-07 | 舒泰神(北京)生物制药股份有限公司 | 特异性识别cd40的抗体及其应用 |
CN115812082A (zh) * | 2021-07-14 | 2023-03-17 | 舒泰神(北京)生物制药股份有限公司 | 特异性识别cd40的抗体及其应用 |
WO2023186111A1 (zh) * | 2022-04-02 | 2023-10-05 | 和铂医药(上海)有限责任公司 | 一种靶向cd40的抗原结合蛋白及其制备和应用 |
Family Cites Families (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
US7183387B1 (en) | 1999-01-15 | 2007-02-27 | Genentech, Inc. | Polypeptide variants with altered effector function |
GB2353887B (en) | 1999-09-04 | 2003-09-24 | Ibm | Speech recognition system |
WO2003028809A1 (en) * | 2001-10-02 | 2003-04-10 | Chiron Corporation | Methods of therapy for b-cell malignancies |
US20080199471A1 (en) | 2002-03-01 | 2008-08-21 | Bernett Matthew J | Optimized cd40 antibodies and methods of using the same |
US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
US7662925B2 (en) | 2002-03-01 | 2010-02-16 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
US20060235208A1 (en) | 2002-09-27 | 2006-10-19 | Xencor, Inc. | Fc variants with optimized properties |
US9051373B2 (en) | 2003-05-02 | 2015-06-09 | Xencor, Inc. | Optimized Fc variants |
JP4765037B2 (ja) * | 2003-11-04 | 2011-09-07 | ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド | 慢性リンパ球性白血病の処置のためのアンタゴニスト抗cd40モノクローナル抗体の使用 |
DE602004028272D1 (de) * | 2003-11-04 | 2010-09-02 | Novartis Vaccines & Diagnostic | Verwendung von antagonisten-anti-cd40-monoklonalen antikörpern zur behandlung von multiplem myelom |
DK1682178T3 (da) * | 2003-11-04 | 2010-10-04 | Novartis Vaccines & Diagnostic | Fremgangsmåder til terapi af cancere der udtrykker CD-40-antigenet |
CA2564296A1 (en) * | 2004-04-27 | 2006-07-13 | Novartis Vaccines And Diagnostics, Inc. | Antagonist anti-cd40 monoclonal antibodies and methods for their use |
DK2471813T3 (en) | 2004-07-15 | 2015-03-02 | Xencor Inc | Optimized Fc variants |
US20080057070A1 (en) * | 2004-11-04 | 2008-03-06 | Chiron Corporation | Antagonist Anti-Cd40 Monoclonal Antibodies and Methods for Their Use |
US20150315284A1 (en) | 2004-11-09 | 2015-11-05 | Xencor, Inc. | OPTIMIZED Fc VARIANTS |
WO2007047578A2 (en) | 2005-10-14 | 2007-04-26 | Medimmune, Inc. | Cell display of antibody libraries |
WO2008091954A2 (en) | 2007-01-23 | 2008-07-31 | Xencor, Inc. | Optimized cd40 antibodies and methods of using the same |
AU2008247819B2 (en) | 2007-05-01 | 2013-02-14 | Research Development Foundation | Immunoglobulin Fc libraries |
JP5809415B2 (ja) | 2007-11-09 | 2015-11-10 | ペレグリン ファーマシューティカルズ,インコーポレーテッド | 抗vegf抗体の組成物および方法 |
US10053513B2 (en) | 2009-11-30 | 2018-08-21 | Janssen Biotech, Inc. | Antibody Fc mutants with ablated effector functions |
AP4082A (en) * | 2010-03-31 | 2017-03-29 | Boehringer Ingelheim Int | Anti-cd40 antibodies |
WO2012046745A1 (ja) | 2010-10-04 | 2012-04-12 | 独立行政法人理化学研究所 | Mhcクラスiiを発現する悪性腫瘍の治療薬 |
AR083847A1 (es) | 2010-11-15 | 2013-03-27 | Novartis Ag | Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40 |
WO2012088461A2 (en) | 2010-12-23 | 2012-06-28 | Biogen Idec Inc. | Linker peptides and polypeptides comprising same |
US9475879B2 (en) | 2011-04-21 | 2016-10-25 | Bristol-Myers Squibb Company | Antibody polypeptides that antagonize CD40 |
EP2702078B1 (en) * | 2011-04-29 | 2018-11-07 | Apexigen, Inc. | Anti-cd40 antibodies and methods of use |
TW201817745A (zh) | 2011-09-30 | 2018-05-16 | 日商中外製藥股份有限公司 | 具有促進抗原清除之FcRn結合域的治療性抗原結合分子 |
CA2850194C (en) | 2011-09-30 | 2023-03-21 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule for promoting elimination of antigens |
SG10201704849PA (en) | 2012-02-09 | 2017-07-28 | Chugai Pharmaceutical Co Ltd | Modified fc region of antibody |
GB201203051D0 (en) | 2012-02-22 | 2012-04-04 | Ucb Pharma Sa | Biological products |
US11180572B2 (en) | 2012-07-06 | 2021-11-23 | Genmab B.V. | Dimeric protein with triple mutations |
TWI717591B (zh) | 2012-08-24 | 2021-02-01 | 日商中外製藥股份有限公司 | FcγRIIb特異性Fc區域變異體 |
JP6693745B2 (ja) * | 2012-10-30 | 2020-05-13 | アペクシジェン, インコーポレイテッド | 抗cd40抗体および使用方法 |
US20140294812A1 (en) | 2013-03-15 | 2014-10-02 | Xencor, Inc. | Fc variants that improve fcrn binding and/or increase antibody half-life |
SG11201508170TA (en) | 2013-04-02 | 2015-11-27 | Chugai Pharmaceutical Co Ltd | Fc REGION VARIANT |
GB201308658D0 (en) | 2013-05-14 | 2013-06-26 | Isis Innovation | Antibodies |
EP3113796A1 (en) | 2014-03-07 | 2017-01-11 | Bristol-Myers Squibb Company | Method of using antibody polypeptides that antagonize cd40 to treat ibd |
WO2016020309A1 (en) | 2014-08-04 | 2016-02-11 | F. Hoffmann-La Roche Ag | Bispecific t cell activating antigen binding molecules |
JP6586454B2 (ja) * | 2014-08-14 | 2019-10-02 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | ヒトcd40を活性化する抗体とヒトpd−l1に対する抗体との併用療法 |
WO2016028810A1 (en) | 2014-08-18 | 2016-02-25 | Biogen Ma Inc. | Anti-cd40 antibodies and uses thereof |
MY189836A (en) | 2014-11-21 | 2022-03-11 | Bristol Myers Squibb Co | Antibodies against cd73 and uses thereof |
CR20170592A (es) * | 2015-05-29 | 2018-02-13 | Abbvie Inc | Anticuerpos anti-cd40 y sus usos |
MX2017016253A (es) | 2015-06-29 | 2018-04-20 | Squibb Bristol Myers Co | Anticuerpos para cd40. |
EA201890162A1 (ru) | 2015-06-29 | 2018-07-31 | Бристол-Маерс Сквибб Компани | Антитела к cd40 с повышенной агонистической активностью |
AU2016331819B2 (en) | 2015-09-30 | 2023-08-24 | Janssen Biotech, Inc. | Agonistic antibodies specifically binding human CD40 and methods of use |
CA3037264A1 (en) | 2016-10-06 | 2018-04-12 | Glaxosmithkline Intellectual Property Development Limited | Antibodies with reduced binding to process impurities |
AU2018236218A1 (en) | 2017-03-14 | 2019-09-12 | Bristol-Myers Squibb Company | Antibodies binding to vista at acidic pH |
US20200095323A1 (en) | 2017-03-20 | 2020-03-26 | The General Hospital Corporation | MITIGATING Fc-Fc RECEPTOR INTERACTIONS IN CANCER IMMUNOTHERAPY |
ES2923143T3 (es) | 2017-05-25 | 2022-09-23 | Bristol Myers Squibb Co | Anticuerpos monoclonales antagonistas contra CD40 y sus usos |
KR20200012907A (ko) | 2017-05-25 | 2020-02-05 | 브리스톨-마이어스 스큅 컴퍼니 | 변형된 IgG1 Fc 도메인 및 그와의 항-CD40 도메인 항체 융합체 |
AU2018272852A1 (en) | 2017-05-25 | 2019-11-28 | Bristol-Myers Squibb Company | Antibodies comprising modified heavy constant regions |
AU2018361743A1 (en) | 2017-11-03 | 2020-04-09 | Novartis Ag | Anti-CD40 antibodies for use in treatment of Sjogren's syndrome |
AR117091A1 (es) | 2018-11-19 | 2021-07-07 | Bristol Myers Squibb Co | Anticuerpos monoclonales antagonistas contra cd40 y sus usos |
JP2022513653A (ja) | 2018-11-28 | 2022-02-09 | ブリストル-マイヤーズ スクイブ カンパニー | 修飾された重鎖定常領域を含む抗体 |
-
2019
- 2019-11-15 AR ARP190103362A patent/AR117091A1/es unknown
- 2019-11-18 US US16/686,596 patent/US11261258B2/en active Active
- 2019-11-18 AU AU2019385331A patent/AU2019385331A1/en active Pending
- 2019-11-18 PE PE2021000727A patent/PE20211293A1/es unknown
- 2019-11-18 BR BR112021009140-8A patent/BR112021009140A2/pt unknown
- 2019-11-18 CA CA3120358A patent/CA3120358C/en active Active
- 2019-11-18 CN CN201980076479.8A patent/CN113164781B/zh active Active
- 2019-11-18 EP EP19818398.0A patent/EP3883652A1/en active Pending
- 2019-11-18 KR KR1020217018573A patent/KR102627246B1/ko active IP Right Grant
- 2019-11-18 CN CN202310098945.0A patent/CN116003608B/zh active Active
- 2019-11-18 SG SG11202104776VA patent/SG11202104776VA/en unknown
- 2019-11-18 WO PCT/US2019/062011 patent/WO2020106620A1/en active Application Filing
- 2019-11-18 MX MX2021005565A patent/MX2021005565A/es unknown
- 2019-11-18 JP JP2021527208A patent/JP7271666B2/ja active Active
- 2019-11-18 EA EA202191359A patent/EA202191359A1/ru unknown
- 2019-11-19 TW TW108142021A patent/TWI800694B/zh active
-
2020
- 2020-10-26 US US17/080,626 patent/US11254750B2/en active Active
-
2021
- 2021-05-11 CL CL2021001230A patent/CL2021001230A1/es unknown
- 2021-05-11 IL IL283104A patent/IL283104A/en unknown
- 2021-05-18 ZA ZA2021/03353A patent/ZA202103353B/en unknown
- 2021-06-11 CO CONC2021/0007691A patent/CO2021007691A2/es unknown
-
2022
- 2022-01-19 US US17/579,468 patent/US11926673B2/en active Active
- 2022-01-31 US US17/588,518 patent/US11773178B2/en active Active
- 2022-02-11 US US17/670,223 patent/US11795231B2/en active Active
-
2023
- 2023-04-26 JP JP2023072027A patent/JP2023106402A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR117091A1 (es) | Anticuerpos monoclonales antagonistas contra cd40 y sus usos | |
CO2019012151A2 (es) | Formulaciones estables de anticuerpos contra el receptor de muerte programada 1 (pd-1) y métodos para su uso | |
PE20200485A1 (es) | Proteinas de union a antigenos trem2 y usos de estas | |
CL2020001974A1 (es) | Anticuerpos anti-trem2 y métodos para utilizarlos. (divisional solicitud 201903093) | |
CO2018005932A2 (es) | Moléculas biespecíficas que tienen inmunorreactividad con pd-1 y ctla-4, y métodos de uso de las mismas | |
PE20181349A1 (es) | Anticuerpos biespecificos con tetravalencia para un receptor de fnt coestimulador | |
CL2020000263A1 (es) | Conjugado de anticuerpo monoclonal contra bcma-fármaco. | |
AR107303A1 (es) | Métodos de tratamiento de cánceres positivos para ace utilizando antagonistas de unión a eje pd-1 y anticuerpos biespecíficos anti-ace / anti-cd3, uso, composición, kit | |
CO2020000438A2 (es) | Anticuerpos anti-ctla-4 y sus usos | |
AR111830A1 (es) | Anticuerpos monoclonales antagonistas contra cd40 y sus usos | |
CR20160319A (es) | Anticuerpo pd-1, fragmento de union al antigeno de este y uso médico de este | |
CL2020002075A1 (es) | Métodos para tratar el cáncer con anticuerpos anti-pd1. | |
MA44594B1 (fr) | Anticorps anti-ctla-4 et méthodes d'utilisation de ceux-ci | |
AR101829A1 (es) | Tratamiento de cáncer utilizando un receptor quimérico de antígeno cll-1 | |
EA201792221A1 (ru) | Антитела против сортилина и способы их применения | |
NI201300051A (es) | Uso de células t de receptor modificado antígeno quiméricas para tratar el cáncer. | |
CL2020001619A1 (es) | Anticuerpos anti-cd33 y métodos para utilizarlos. (divisional solicitud 201903095) | |
CO2019012143A2 (es) | Formulaciones estables de anticuerpos anti-ctla4 solos y en combinación con anticuerpos contra el receptor de muerte programada 1 (pd-1) y métodos para su uso | |
CY1112883T1 (el) | Εξανθρωπισμενα αντισωματα αντι-cd19 και οι χρησεις τους στην θεραπεια ογκων, μεταμοσχευσης και ασθενειων αυτο-ανοσιας | |
BR112013027829A2 (pt) | anticorpos anti-cd40 e método de uso | |
BR112014007426A2 (pt) | anticorpos contra tl 1a e seus usos | |
PE20120079A1 (es) | Moleculas de anticuerpos mejoradas | |
CL2020002446A1 (es) | Anticuerpos contra mica y/o micb y sus usos | |
BR112016022013A2 (pt) | anticorpos monoclonais para fator de crescimento e diferenciação 15 (gdf-15) e usos dos mesmos para tratamento de caquexia do câncer e câncer | |
CO2021012719A2 (es) | Métodos para producción de células car-nk y uso de las mismas |